Omeros Corporation (OMER)

Currency in USD
14.260
+0.340(+2.44%)
Real-time Data·
OMER is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.13014.534
52 wk Range
6.70221.240
Key Statistics
Prev. Close
13.92
Open
14.13
Day's Range
14.13-14.534
52 wk Range
6.702-21.24
Volume
65.83K
Average Volume (3m)
1.38M
1-Year Change
66.9412%
Book Value / Share
-1.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OMER Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
27.500
Upside
+92.85%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Omeros Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 27.500
(+92.85% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy22.00+52.68%-Maintain14/10/2026
Cantor Fitzgerald
Buy22.00+52.68%-Upgrade22/09/2026
H.C. Wainwright
Buy33.00+129.02%-Maintain28/07/2026
H.C. Wainwright
Buy33.00+129.02%40.00Maintain29/06/2026
H.C. Wainwright
Buy40.00+177.60%-Maintain10/06/2026

Omeros Corporation Earnings Call Summary for Q3/2026

  • Omeros beat Q3 estimates with adjusted EPS of $0.06 vs. $0.01 expected and revenue of $41.8M vs. $37.27M; shares fell 7.97% after hours.
  • YARTEMLEA sales rose 30% to $41.8M gross, reaching 109 of 175 targeted U.S. transplant centers; net sales hit $35.9M with 14% deductions.
  • Company posted second consecutive quarter of positive operating cash flow at $13.3M; GAAP loss of $57.4M driven by $62M derivative charge.
  • Management expects Q4 revenue momentum to continue with slightly higher operating expenses; no specific 2027 guidance provided yet.
  • NTAP reimbursement provides up to $287K per eligible Medicare case; studies planned for ARDS and pediatric prevention in late 2026/early 2027.
Last Updated: 17/11/2026, 09:54 am
Read Full Transcript

Earnings

Latest Release
16/11/2026
EPS / Forecast
0.06 / 0.01
Revenue / Forecast
41.8M / 37.27M
EPS Revisions
Last 90 days

OMER Income Statement

Compare OMER to Peers and Sector

Metrics to compare
OMER
Peers
Sector
Relationship
P/E Ratio
13.6x0.0x−0.2x
PEG Ratio
0.080.000.00
Price/Book
−11.2x1.1x2.6x
Price / LTM Sales
13.6x1.8x2.7x
Upside (Analyst Target)
97.6%87.9%68.5%
Fair Value Upside
Unlock2.8%11.5%Unlock

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
13.29M18.35%221.59M
Other Institutional Investors
23.18M32.03%386.70M
Public Companies & Retail Investors
35.92M49.62%599.14M
Total
72.39M100.00%1.21B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.35%6,044,633100,824
Ingalls & Snyder, LLC5.06%3,659,52361,041

People Also Watch

56.620
LQDA
-0.19%
63.75
ETON
+0.15%
71.02
CBRL
+2.08%
21.375
AMRX
+1.21%

FAQ

What Is the Omeros (OMER) Stock Price Today?

The Omeros stock price today is 14.260 USD.

What Stock Exchange Does Omeros Trade On?

Omeros is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Omeros?

The stock symbol for Omeros is "OMER."

What Is the Omeros Market Cap?

As of today, Omeros market cap is 1.040B USD.

What Is Omeros's Earnings Per Share (TTM)?

The Omeros EPS (TTM) is 1.03.

When Is the Next Omeros Earnings Date?

Omeros will release its next earnings report on 05/04/2027.

From a Technical Analysis Perspective, Is OMER a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Omeros Stock Split?

Omeros has split 0 times.

How Many Employees Does Omeros Have?

Omeros has 175 employees.

What is the current trading status of Omeros (OMER)?

As of 18/11/2026, Omeros (OMER) is trading at a price of 14.260 USD, with a previous close of 13.920 USD. The stock has fluctuated within a day range of 14.130 USD to 14.534 USD, while its 52-week range spans from 6.702 USD to 21.240 USD.

What Is Omeros (OMER) Price Target According to Analysts?

The average 12-month price target for Omeros is 27.500 USD, with a high estimate of 33 USD and a low estimate of 22 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +92.85% Upside potential.

What Is the OMER Premarket Price?

OMER's last pre-market stock price is 14.120 USD. The pre-market share volume is 4,260.000, and the stock has decreased by 0.200, or 1.440%.

What Is the OMER After Hours Price?

OMER's last after hours stock price is 13.980 USD, the stock has decreased by 0.060, or 0.430%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.